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Early diagnosis and prompt treatment are the goals of mod-
ern therapy, but there are no randomized controlled trials to 
guide treatment and the published literature contains a high 
ratio of reviews to original data. Much of that data comes 
from case reports and often small, retrospective series with 
no clearly defined treatment criteria.
Methods A study group of the European Society for 
Trauma and Emergency Surgery (ESTES) was formed in 
2013 with the aim of developing guidelines for the man-
agement of AMI. A comprehensive literature search was 
performed using the Medical Subject Heading (MeSH) 
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thesaurus keywords “mesenteric ischaemia”, “bowel 
ischaemia” and “bowel infarction”. The bibliographies of 
relevant articles were screened for additional publications. 
After an initial systematic review of the literature by the 
whole group, a steering group formulated questions using a 
modified Delphi process. The evidence was then reviewed 
to answer these questions, and recommendations formu-
lated and agreed by the whole group.
Results The resultant recommendations are presented in 
this paper.
Conclusions The aim of these guidelines is to provide 
recommendations for practice that will lead to improved 
outcomes for patients.
Keywords Acute mesenteric ischaemia · Diagnosis · 
Clinical management · Guidelines
Introduction
AMI accounts for about 1:1000 acute hospital admissions 
in Europe and the USA [1]. In Japan, where the incidence 
of vascular disease is lower, this figure has been estimated 
at 1:10,000 [2]. The incidence appears to be increasing due 
to an ageing general population with increasing prevalence 
of comorbidities. This pre-existing disease worsens the 
prognosis of intestinal necrosis [3].
The diagnosis of AMI is difficult and it will often go 
unrecognized as a cause of death. A population-based study 
from a national general practitioner database in the UK 
estimated the overall incidence of AMI at 0.63 per 100,000 
person years [4], while a population-based study in Sweden 
with an 87 % autopsy rate estimated the incidence more than 
twenty times higher at 12.9 per 100,000 person years [5]. 
Sixty-five percent of acute superior mesenteric artery occlu-
sions were diagnosed at autopsy. The incidence increases 
exponentially with age and there appears to be an equal inci-
dence in men and women after adjusting for age and gender 
in the population [5]. While the mean age is around 70 years 
in most studies, several report cases in their 20 s [2, 6–9].
Four different aetiological forms of AMI have been 
identified: arterial embolism (EAMI), arterial thrombosis 
(TAMI), venous thrombosis (VAMI) and non-occlusive 
mesenteric ischaemia (NOMI). Although they have differ-
ent clinical and pathophysiological features this does not 
facilitate early diagnosis of the disease.
Twenty-five percent of the cardiac output goes to the 
splanchnic circulation at rest increasing to 35 % in the 
postprandial state. Seventy percent of mesenteric blood 
flows to the mucosa and submucosa [10] and microscopic 
changes of ischaemia can be detected within minutes [11]. 
Although the gut can survive a 75 % reduction in blood 
flow for up to 12 h without significant injury [12], irrevers-
ible bowel damage occurs within 6 h of complete vascular 
occlusion [13].
Untreated, AMI will cause mesenteric infarction, intes-
tinal necrosis, an overwhelming inflammatory response 
and death. Early intervention can halt and reverse this pro-
cess leading to a full recovery while failure to recognize 
AMI before intestinal necrosis has developed is respon-
sible for the high mortality of the disease [14–16]. Early 
diagnosis and prompt treatment are the goals of modern 
therapy, but diagnosis is difficult particularly in the early 
stages when intervention would be of most benefit. A high 
index of suspicion in the elderly patient with pain out 
of proportion to clinical signs and an untreated cardiac 
arrhythmia is not an adequate baseline. In many studies up 
to 20 % of patients had no pain recorded [2, 6, 7, 17–24] 
and in one study 65 % of patients were intubated at the 
time of referral [25]. Moreover, many patients have perito-
nitis at presentation.
Although mortality rates have declined over the past 
50 years [5, 26] they remain unacceptably high at 50–69 % 
[6, 27–29]. Overall 26 % of people admitted to hospital 
with acute mesenteric ischaemia will be alive a year later. 
However, those patients who are discharged alive have a 
reasonably good prognosis given the prevalence of signifi-
cant co-morbidities among that cohort with 84 % alive at 
one year and 50–77 % at 5 years [18, 30–32]. Ten year sur-
vival of almost 30 % has been reported [18, 32]. A median 
survival of 52 months has been reported in patients with 
arterial occlusive AMI who survived their acute hospital 
admission [9].
There are no randomized controlled trials to guide treat-
ment and the published literature contains a high ratio of 
reviews to original data. Much of that data comes from case 
reports and often small, retrospective series with no clearly 
defined treatment criteria.
The aim of these guidelines is to provide recommenda-




For the purpose of these guidelines, acute mesenteric 
ischaemia (AMI) is defined as sudden acute arterial or 
venous occlusion or drop in circulating pressure resulting 
in insufficient blood flow within the mesenteric circulation 
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to meet the metabolic demands placed upon it. Isolated 
colonic ischaemia and focal segmental ischaemia second-
ary to adhesions, hernias or other forms of extrinsic com-
pression are excluded. Chronic mesenteric ischaemia and 
ischaemic colitis are separate entities and are not consid-
ered in these guidelines.
Search strategy and consensus approach
The European Society for Trauma and Emergency Surgery 
(ESTES) Study Group was formed in 2013 with the aim of 
developing guidelines for the management of AMI. Com-
prehensive computer database literature searches were per-
formed using the indexed online database MEDLINE/Pub-
Med using the Medical Subject Heading (MeSH) thesaurus 
keywords “mesenteric ischaemia”, “bowel ischaemia” and 
“bowel infarction”. Searches were limited to human stud-
ies. Abstracts from original publications were screened for 
relevance and full publications evaluated where appropri-
ate. Lists of quoted literature within these articles were also 
screened for additional relevant publications.
After an initial systematic review of the literature by the 
whole group, the steering group formulated questions using 
a modified Delphi process [33]. The evidence was reviewed 
and recommendations formulated and agreed by the whole 
group. The classification system used to determine the 
strength of evidence (LOE) is given in Table 1 [34].
Presentation and clinical diagnosis
Which clinical factors should arouse suspicion of AMI 
in the acute abdomen?
Answer: Most patients present with abdominal pain of 
sudden onset. The early phase of AMI can be character-
ized by an initial discrepancy between the severity of the 
abdominal pain and minimal findings on physical exami-
nation. Patients can also present with symptoms of nausea, 
vomiting and initial forced evacuation, early in the course 
of the disease. The location of pain varies, but as ischemia 
progresses to infarction, it becomes diffuse. The develop-
ment of transmural infarction may also be signalled by 
fever, bloody diarrhoea and shock.
Background: The available evidence comes from level 
II and III studies, with mostly small and retrospective 
observational case-series. However, they all consider pain 
as the main symptom in most cases [14, 35]. The classical 
presentation has been described as pain out of proportion 
to the findings on clinical examination [10, 19, 36–41] but 
in 20 to 25 % of patients the initial presentation resembles 
an acute abdomen from another cause [36, 42, 43]. Other 
frequent symptoms associated with pain in the early course 
include nausea (93 %), vomiting (80 %) and diarrhoea 
(48 %) [19, 40, 41]. Klass’ classical description [44] of the 
onset of abdominal pain with sudden simultaneous passage 
of stools as a characteristic sign of AMI is also reported in 
recent studies [39, 43, 45]. However, these symptoms are 
not specific for AMI.
Features in the patient’s medical history can be impor-
tant, particularly in the elderly presenting with 2–3 h of 
continuous abdominal pain [46]. A retrospective series of 
215 AMI patients identified significant comorbidities that 
predispose to AMI such as ischaemic heart disease, atrial 
fibrillation, hypertension, diabetes mellitus or renal insuffi-
ciency in most patients [47]. Another retrospective series of 
47 patients over 13 years observed atrial fibrillation in all 
14 patients with arterial embolism and ischemic cardiomy-
opathy in 18 of 20 cases of arterial thrombosis [48]. As the 
disease progresses and ischemia leads to intestinal necrosis, 
pain becomes more diffuse and signs of peritoneal irrita-
tion [14] and bloating appear [39]. The patient may develop 
bloody diarrhoea, fever, signs of shock, multiple organ fail-
ure and a reduction in consciousness [37, 39].
Recommendation: Acute mesenteric ischaemia (AMI) 
should be suspected in patients with acute abdominal pain 
in whom there is no clear diagnosis, particularly when the 
pain is disproportionate to the physical examination find-
ings and in the elderly with a history of cardiovascular 
comorbidities (LOE: III).
Table 1  Classification system 
used to determine strength of 
evidence
Level of evidence Definition
IA Evidence from meta-analysis of randomized controlled trials
IB Evidence from at least one randomized controlled trial
IIA Evidence from at least one controlled study without randomization
IIB Evidence from at least one other type of quasi-experimental study
III Evidence from non-experimental descriptive studies such as comparative studies, cor-
relation studies and case controlled-studies
IV Evidence from expert committee reports or opinions or clinical experience of respected 
authorities or both
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Are there any clinical features to distinguish the 
aetiology of AMI?
Answer: Clinical assessment does not reliably distinguish 
between mesenteric arterial embolism or arterial thrombo-
sis. However, the four aetiological types of AMI have been 
associated with different characteristics and risk factors 
(Table 2). EAMI is characterized by a sudden onset of pain 
and is frequently associated with atrial fibrillation. TAMI 
has a more indolent course and is often associated with a 
history of abdominal angina and weight loss suggestive of 
undiagnosed chronic mesenteric ischaemia. VAMI appears 
in younger patients, sometimes with several days of mild 
symptoms. It is associated with hypercoagulable states, cir-
rhosis, severe pancreatitis, abdominal trauma and advanced 
malignancy. NOMI is often silent as it occurs in patients 
that are critically ill and often ventilated.
Background: Embolism is the most frequent cause of 
mesenteric ischaemia (45 %) [10]. Cardiac ischemia, tach-
yarrhythmia, rheumatic fever, and other conditions that pre-
dispose to the formation of atrial thrombi are risk factors of 
the disease [35, 36, 38, 42, 49].
Approximately 33 % of patients present with a history 
of recent embolism [36, 39] and the absence of suitable 
anticoagulant treatment in these patients should increase 
suspicion of EAMI [21, 35, 36, 42]. The sudden onset of 
severe pain with spontaneous emptying of the bowel (vom-
iting and diarrhoea) but no significant physical findings is a 
classic sign of an EAMI. If a potential source of emboli can 
be identified, this “clinical triad” is present in 40–80 % of 
patients [38].
Arterial thrombosis accounts for approximately 25 % of 
cases of AMI [10]. These patients usually report prodromal 
symptoms of mesenteric angina [36] (postprandial abdomi-
nal pain, nausea and weight loss) before the acute episode 
resulting from pre-existent vascular insufficiency [10, 39]. 
The main risk factors for TAMI are atherosclerotic disease 
and dyslipidaemia [49, 50]. There may be a history of other 
vascular events and previous vascular surgery.
Venous thrombosis represents 10 % of cases of patients 
with acute mesenteric ischaemia and usually occurs in a 
younger population. While thromboembolic AMI is more 
common in the over 60 s, VAMI tends to occur in people 
over 40 [36, 47, 51, 52]. Although occasionally idiopathic, 
most patients have an identifiable risk factor [10, 51, 53]. 
Up to 50 % of patients with VAMI report a previous deep 
venous thrombosis or pulmonary embolism [54]. Other 
risk factors include hypercoagulability states (protein C 
and S deficiency, polycythaemia or Leiden factor V muta-
tion), portal hypertension, abdominal trauma, abdominal 
infection, acute pancreatitis, malignancy, nephrotic syn-
drome, cirrhosis or splenomegaly [10, 40, 49, 51–53, 55–
57]. Leiden factor V mutation is the most common associ-
ated hypercoagulability state and is reported in 20–40 % 
of VAMI cases [40]. Oral contraceptives, pregnancy and 
the puerperium are risk factors in young women [35, 58]. 
Venous vascular occlusion is usually peripheral, involving 
short segments of bowel [53]. The onset of VAMI is char-
acterized by subacute abdominal pain that may develop 
over a period of up to 2 weeks. Half of the patients com-
plain of nausea and vomiting. Untreated cases may result 
in portal hypertension with the development of oesopha-
geal varices [39]. VAMI is not usually associated with 
postprandial syndrome, although bloating, abdominal dis-
tension, fever and occult blood in stools may be present 
[59].
NOMI is responsible for about 20 % of cases of mesen-
teric ischaemia. It usually occurs in patients that are criti-
cally ill, sedated and artificially ventilated and is difficult to 
recognize. It is poorly understood, but can be explained by 
a combination of low cardiac output and vasoconstriction. 
Risk factors for NOMI include age over 50, history of acute 
myocardial infarction, congestive heart failure, aortic insuf-
ficiency, cardiopulmonary bypass, kidney or liver disease 
Table 2  Characteristics and risk factors associated with AMI
Associated comorbidities Onset of pain Associated symptoms Related procedures
EAMI Heart disease (atrial fibrillation, rheumatic, myocardial 
infarction, prosthetic valve, ventricular aneurism, 
Chagas’ disease)
Acute Diarrhoea, vomiting Angiography
TAMI Arteriosclerosis, hypertension, diabetes, hyperlipidemia, 
dehydration, antiphospholipid syndrome, estrogens
Acute, may be  
recurrent




VAMI Hypercoagulable disorders, sickle cell disease, right  
sided heart failure, DVT, malignancies, hepatitis,  
pancreatitis, sepsis hepato-splenomegaly, cirrhosis
Gradual Vague complaints Recent abdominal 
surgery
NOMI Shock, hypovolemia, hypotension, digitalis, diuretics, 
beta-blockers, alpha-adrenergics, enteral nutrition,  
critical care support
Either acute or gradual
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or major abdominal surgery. Notably, many patients with 
NOMI may have none of these factors [10].
The diagnosis should be suspected in patients with mes-
enteric hypoperfusion secondary to circulatory shock or 
vasoactive drugs (including amines, cocaine and digitalis) 
when there is a significant unexpected deterioration in their 
clinical course [40, 41, 43, 60]. Acute or insidious pain 
(without defecation), bloating, abdominal distension and 
the presence of occult blood in the stools are all consistent 
with NOMI in a critically ill patient [10, 21, 36, 45, 54]. 
Most patients display signs of sepsis and abdominal disten-
sion as a late clinical sign [10].
Mitsuyoshi et al. [61] suggested diagnostic criteria for 
NOMI in the critically ill patient consisting of 3 of: ileus 
or abdominal pain, need for catecholamines, episode of 
hypotension or rising level of transaminases. Although they 
were able to demonstrate early detection and improved sur-
vival, the numbers involved were small.
Large doses of vasopressors alone can cause bowel 
ischaemia by non-occlusive, low perfusion mechanisms 
(NOMI). AMI has been associated with drug toxicity. 
Several case reports link cardiotoxins, such as digitalis, 
in combination with furosemide-induced fluid depletion, 
calcium-channel blockers [36], cocaine (linked to arterial 
thrombosis), organophosphates, ergotamine, phenobarbi-
tal, ethylene glycol or tricyclic antidepressants to NOMI in 
ICU patients. Snake bites have also been associated with 
NOMI [62, 63].
NOMI has also been described in patients who have 
undergone the stress of a surgical procedure or trauma 
and are receiving enteral nutrition in intensive care units. 
The reported incidence of AMI in these patients is 0.3–
8.5 % [10, 64]. The proposed mechanism is an imbalance 
between demand (created by the enteral feeding) and sup-
ply (decreased by systemic hypo-perfusion and mesenteric 
vasoconstriction).
Recommendations: AMI secondary to an arterial embo-
lism (EAMI) should be suspected in patients with atrial 
fibrillation who have a sudden onset of abdominal pain. 
AMI resulting from arterial thrombosis (TAMI) should 
be suspected in patients with evidence of atherosclerotic 
disease particularly with a recent history of postprandial 
syndrome. AMI due to venous thrombosis (VAMI) should 
be suspected in patients with hypercoagulable states. Non-
occlusive mesenteric ischaemia (NOMI) should be sus-
pected in critically ill patients with an unexpected deterio-
ration in their clinical condition (LOE: III).
Can interventional procedures precipitate AMI?
Answer: Any procedure which involves vascular manipula-
tion (even unintentional) can precipitate AMI.
Background: Acute mesenteric ischaemia has been 
associated with several procedures and may complicate any 
abdominal surgery [21]. VAMI is a recognised complica-
tion of laparoscopic colorectal surgery. A retrospective 
analysis over 10 years (1069 colorectal operations) identi-
fied 37 (3.5 %) cases of AMI. Inflammatory bowel disease, 
ulcerative colitis, preoperative therapy with steroids, opera-
tive time longer than 220 min, ileoanal pouch anastomosis, 
total proctocolectomy or postoperative septic complica-
tions were associated with thrombosis. The latter two were 
independent predictors of thrombosis in multivariate anal-
ysis. Manipulation of mesenteric vessels and raised intra-
abdominal pressure may play a role in the pathophysiology 
[65].
EAMI may occur when atheromatous plaques are dis-
lodged by angiography of the coronary or cerebral circu-
lation [10]. Aortic catheterization can induce cholesterol 
embolization [59].
AMI may be seen after colonoscopy. The decreased 
intravascular volume resulting from fasting and colon 
preparation, reduction of vascular tone through medica-
tions used for conscious sedation and the mechanical 
effects of colonoscopy may work together to create a low 
flow state precipitating acute mesenteric ischemia [66]. 
Possible predisposing conditions include connective tis-
sue disease, advanced age, cardiovascular disease and 
immunosuppression.
AMI is an infrequent event after coronary bypass (1 %) 
or valve replacement surgery (0.2–0.4 %). It occurs particu-
larly in older, dehydrated patients who have generalized 
atherosclerosis, and has a 70–100 % mortality [67]. Several 
factors (low cardiac output, use of vasopressors and under-
lying atherosclerotic disease) contribute to severe hypoper-
fusion and NOMI is the most frequent pathophysiological 
event [41]. Intra-aortic balloon pumps cause embolic show-
ers particularly if placement involves excessive manipula-
tion of a diseased aorta [50].
Recommendation: Unexplained abdominal pain after 
any invasive procedure, particularly involving vascular 
manipulation, should lead to suspicion and investigation of 
AMI (LOE: III).
Can we predict prognosis at presentation, in order 
to help the decision making process?
Answer: It is difficult to predict prognosis at presenta-
tion based exclusively on clinical findings. However, older 
patients with delayed presentation and abdominal signs of 
peritonitis or organ failure generally have a worse prog-
nosis. A number of scoring systems have been proposed 
for AMI, but these have not been validated in large-scale 
studies.
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Background: The moribund patient with significant 
co-morbidities and poor performance status is unlikely to 
benefit from intervention. A number of factors including 
admission from a nursing home, or partial dependence, 
pre-existing ‘do not attempt resuscitation’ order, and class 
4 wound before surgery are all associated with increased 
mortality [68]. So too are coma, artificial ventilation, acute 
renal failure, chronic obstructive pulmonary disease, myo-
cardial infarction within the preceding 6 months as well as 
preoperative sepsis, major surgery, emergency procedure, 
duration of surgery and postoperative complications [68].
Most of the literature considers old age and late diagno-
sis as bad prognostic factors for arterio-occlusive disease. 
However, in VAMI longer duration of symptoms before 
hospital admission may be related to better outcome. With 
arterio-occlusive AMI a cut off point of 60-65 years and 
24 h from the onset of symptoms are associated with bet-
ter prognosis [7, 14, 21, 30]. One study reported thirty day 
survival of 81 % for patients with AMI under the age of 71. 
This fell to 30 % between 71 and 84 and 7 % in the over 
84 s [28]. It was associated with increasing rates of non-
resectable gangrene in these age groups of 9, 45 and 79 %, 
respectively.
In a series of patients with AMI mortality was 10.6 % 
if operated in the first 24 h after onset of symptoms vs. 
72.9 % if operated after 24 h [14].
In arterial occlusion, all symptoms but abdominal pain 
indicate disease progression. The presence of peritoneal 
irritation is associated with bowel necrosis and worse prog-
nosis [14, 42]. Renal failure and acidosis resulting from 
shock and sepsis are independent risk factors for mortality 
[7, 35].
In a retrospective study of 58 patients resection (at first 
or second look procedure) and no recent major cardiovas-
cular intervention were associated with better survival rates 
[21]. A larger retrospective series of 124 patients identified 
older age, bandemia, elevated serum aspartate aminotrans-
ferase, increased blood urea nitrogen and metabolic acido-
sis as independent predictors of death in AMI [7].
APACHE-II and P-POSSUM are not accurate scoring 
systems for outcomes after emergency surgery and P-POS-
SUM may under-predict mortality from AMI [69]. How-
ever, they may provide a useful indicator of morbidity and 
mortality. Other scoring systems for predicting outcome 
from AMI have shown early promise, but require validation 
in further studies [2, 30, 68].
Recommendation: Management decisions should not 
be based exclusively on clinical findings. However, patients 
with advanced age, late presentation, peritonitis and signs 
of organ failure are unlikely to benefit from invasive pro-
cedures and should be considered for palliative care only 
(LOE: III).
Diagnosis
Are there sensitive and specific laboratory tests that can 
be used for early detection of AMI?
Answer: There is no specific laboratory test that can be 
routinely used for early detection of AMI.
Background: The ideal plasma biomarker for AMI 
should be specific for bowel ischemia and highly sensi-
tive. As ischemia starts from the mucosa and progresses to 
the serosa, a mucosa-derived marker would be most use-
ful for early diagnosis [70]. The most promising plasma 
markers are intestinal fatty acid binding protein (I-FABP) 
and α-glutathione S-transferase (GST), originating from 
mucosa of the small bowel and D-lactate which is produced 
by gut bacterial organisms such as Escherichia coli [71, 72] 
These markers may have a potential use as early diagnos-
tic tools in AMI, but none of them has yet entered routine 
clinical practice.
Serum L-lactate is a specific marker of tissue hypo-per-
fusion [73]. The liver can clear large quantities of L-lactate 
from the porto-mesenteric circulation and as a result serum 
lactate level does not correlate with intestinal infarction 
[74]. Lactic acidosis develops late in the course of AMI 
with extensive transmural infarction and tissue hypoperfu-
sion due to sepsis. At that point mortality is already in the 
order of 75 % [75].
The fibrinolytic marker D-dimer does not differentiate 
patients with AMI from those with non-acute mesenteric 
ischemia and that there is no difference in D-dimer levels 
between patients with resectable and irresectable bowel 
necrosis [76].
The most common laboratory abnormalities found in 
AMI are hemoconcentration, leukocytosis, metabolic aci-
dosis with high anion gap and lactate concentration, and 
high levels of serum amylase, aspartate aminotransferase, 
lactate dehydrogenase and creatine phosphokinase. None 
of these is sufficiently sensitive or specific to diagnose AMI 
[10, 77].
Recommendations: A normal serum lactate level does 
not exclude AMI and should not be used for diagnosis 
(LOE: III).
Routine laboratory tests reflect disease progression in 
AMI, but should not be used for diagnostic purposes (LOE: 
III).
What is the most sensitive and specific test for the 
detection of AMI?
Answer: The most sensitive and specific diagnostic tool 
is biphasic multidetector computed tomography (MDCT) 
with intravenous contrast.
259ESTES guidelines: acute mesenteric ischaemia
1 3
Background: The diagnostic work-up of AMI requires a 
non-invasive test that confirms the diagnosis and differenti-
ates it from other abdominal pathology.
A plain abdominal radiograph has no role in the early 
detection of AMI, since a normal radiograph does not 
exclude the diagnosis. Radiographic signs in patients with 
AMI are nonspecific and appear when bowel infarction has 
already occurred [78].
Percutaneous angiography has been replaced as the gold 
standard for diagnosis of suspected AMI by MDCT. No rel-
evant trials supporting the use of angiography for diagno-
sis can be found in the recent literature [79, 80]. MDCT 
should be the first line imaging method in suspected AMI 
due to its high diagnostic accuracy [81–85]. This imaging 
modality also allows other causes of acute abdominal pain 
to be excluded.
In this context biphasic CT involves the acquisition 
of scans in the arterial and venous phases. Scans are also 
acquired before intravenous contrast is given. Pre-contrast 
scans detect vascular calcification, hyper-attenuating intra-
vascular thrombus and intramural haemorrhage, while con-
trast-enhanced CT allows the identification of thrombus in 
the mesenteric arteries and veins, abnormal enhancement 
of the bowel wall and the presence of embolism or infarc-
tion of other organs. Sagittal reconstructions are used to 
assess the origin of the mesenteric arteries [83].
The use of oral contrast is generally not feasible in 
patients with AMI. The transit time for oral contrast 
through the bowel will delay definitive treatment in AMI 
and the associated vomiting and an adynamic ileus limit the 
useful passage of oral contrast material [83, 86].
MDCT has a high specificity and sensitivity [82]. A 
meta-analysis of six primary studies using MDCT on 
619 cases with suspected AMI showed a pooled sensitiv-
ity of 93.3 % (95 % confidence interval 82.8, 97.6 %) and 
a pooled specificity of 95.9 % (95 % confidence interval 
91.2, 98.2 %). Among confirmed cases of AMI, final clini-
cal diagnoses were EAMI/TAMI in 69 % of patients, VAMI 
in 15 % and NOMI in 16 % [87].
The high diagnostic accuracy of MDCT is based on spe-
cific features of AMI such as occlusion of mesenteric ves-
sels and the non-specific appearance of bowel wall thicken-
ing and intestinal pneumatosis [88]. Some of these features, 
like diameter of the small mesenteric vessels or gas bub-
bles in intestinal pneumatosis, are no larger than 1–2 mm 
which requires a high spatial resolution achieved with 
MDCT with a collimation of 1.25–2.5 mm in the arterial or 
the portal venous phase [83, 88]. Pneumatosis Intestinalis 
(presence of air within the bowel wall) usually indicates 
transmural infarction in AMI, particularly if it is associated 
with portomesenteric venous gas, but this sign is not spe-
cific for either infarction or ischemia.
NOMI represents the most difficult diagnostic challenge 
in AMI; usually these critically ill patients are sedated and 
intubated and diagnosis may rely only on clinical suspicion 
and imaging studies. The administration of intravenous 
contrast may be contraindicated, hence a lesser sensitivity 
and utility of MDCT [89]. The diagnosis of NOMI should 
be confirmed by selective catheter angiography [90, 91]. 
On CT, the bowel wall of the involved segments may be 
normal or thickened and the pattern of enhancement is vari-
able ranging from absent or diminished to increased, while 
fat stranding of the mesentery and ascites are usually vis-
ible [83].
The CT findings in NOMI are poorly understood [86] 
although in two published papers, with a total of 6 cases, 
that specifically addressed the CT findings of surgically 
and pathologically proven NOMI [92, 93] the reported CT 
findings consisted of diffuse narrowing of the SMA, poor 
visualization of its secondary branches, bowel distension, 
thin and poorly enhancing bowel wall, and intestinal pneu-
matosis which are similar to the findings of acute occlusive 
AMI, except for the absence of thrombus/embolus. The 
most common features associated with AMI are described 
in Table 3.
Recommendations: In cases of suspected AMI, multi-
detector computerised tomography scanning (MDCT) with 
intravenous contrast should be performed immediately. The 
use of oral contrast will add significant delay to the MDCT 
and should be avoided (LOE: III).
Percutaneous angiography should not be used for initial 
diagnosis of AMI except where NOMI is suspected (LOE: 
III).
Is there a role for diagnostic laparoscopy in patients 
with AMI?
Answer: Laparoscopy can be used for diagnosis and 
second-look.
Background: Several articles with small series of 
patients address the use of laparoscopy in AMI [94–96]. 
In cases of uncertainty regarding the diagnosis or the 
extent of bowel necrosis, laparoscopy can offer a mini-
mally invasive way to asses it, even in the ICU (bedside 
laparoscopy). Laparoscopic second-look procedures can 
be offered in a planned or on-demand fashion. However, 
there is no strong evidence to support the routine use of 
laparoscopy in AMI.
Recommendations: There is insufficient evidence to 
support the routine use of laparoscopy in AMI (LOE: IV).
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Treatment
What are the goals of resuscitation and which fluid 
should be used?
Answer: The main goal of resuscitation is the restoration 
of adequate tissue/organ perfusion. Supplementary oxygen 
should be given and crystalloids are the fluid of choice.
Background: The principal goals of managing the 
patient with AMI can be summarized with the 3 “Rs”: 
Resuscitation, Rapid diagnosis and early Revasculariza-
tion before there is significant progression of the systemic 
inflammatory response. The main goal of fluid resuscita-
tion is the restoration of adequate tissue/organ perfusion 
[97–99]. Supplementary oxygen should be given [100] and 
the evaluation of organ delivery of oxygen assessed using 
accepted clinical markers such as peripheral perfusion, 
mental status, and urine output [97, 100].
A recent Cochrane Review [101] has shown no advan-
tage of colloids over crystalloids in reducing mortality 
when used for intravenous fluid resuscitation. The choice 
of fluid will have a cost implication, and colloids are more 
expensive than crystalloids. As there is no evidence that 
colloids improve survival rates or reduce morbidity, crys-
talloids should be preferred on economic grounds. Evi-
dence suggests that the use of hydroxyethyl starch might 
increase mortality and should be avoided until further proof 
of safety can be provided [101–105].
Recommendations: Supplementary oxygen should be 
given immediately (LOE: III).
Fluid volume status should be quickly assessed and fluid 
replacement should start promptly but should not delay 
diagnosis and intervention (LOE: IV).
Crystalloids should be used for fluid replacement, 
hydroxyethyl starch should be avoided (LOE: Ia).
Is there a role for vasopressor drugs?
Answer: Vasopressors reduce splanchnic perfusion and 
should be avoided in AMI whenever possible. Pressors also 
reduce the effectiveness of angiography. However, when 
required consideration should be given to using a pressor 
which has less effect on mesenteric blood flow.
Background: AMI results from insufficient blood flow 
within the mesenteric circulation to meet the metabolic 
demands placed upon it. This may be confounded by hypo-
volaemia and circulatory failure. The use of vasopressors 
to improve cardiac function should be balanced against 
the adverse effect of further splanchnic vasoconstriction 
[3, 106]. Consideration should be given to the use of drugs 
such as dobutamine, low dose dopamine and milrinone, 
which have been shown to have less impact on mesenteric 
blood flow [39]. Vasopressors should not be used until 
the patient has been adequately volume resuscitated. Car-
diac output can also be improved by rate control in atrial 
fibrillation. However, digoxin and other cardiac glycosides 
also reduce flow in the splanchnic circulation and should 
be avoided for the control of atrial fibrillation/flutter in 
patients with AMI [40, 96, 98].
Recommendations: Vasopressor drugs should be 
avoided in AMI. If vasopressor drugs are required after 
adequate volume replacement, preference should be given 
to those with minimal effect on the splanchnic circulation 
(LOE: IV).
Cardiac glycosides should not be used as first line treat-
ment of atrial fibrillation/flutter in AMI (LOE: IV).
Table 3  Radiological features associated with AMI
Modified from Furukawa et al. [83]
SMA superior mesenteric artery, SMV superior mesenteric vein
Characteristic EAMI–TAMI VAMI NOMI
Bowel wall Thinning (“paper thin wall”), 
no change, or thickening with 
reperfusion
Thickening No change or thickening with 
reperfusion
Attenuation of bowel wall on 
unenhanced CT
Not characteristic Low with oedema; high with 
haemorrhage
Not characteristic
Enhancement of bowel wall on 
contrast-enhanced CT
Diminished, absent, target appear-
ance or high with reperfusion
Diminished, absent, target appear-
ance, or increased
Diminished, absent, heterogeneous 
in distribution
Bowel dilatation Not apparent Moderate to prominent Not apparent
Mesenteric vessels Defect or defects in arteries, arte-
rial occlusion, SMA >SMV in 
diameter
Defect or defects in veins, venous 
engorgement
No defect, arterial constriction
Mesentery Not hazy until mesenteric infarc-
tion occurs
Hazy with ascites Not hazy until mesenteric infarc-
tion occurs
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Is there a role for antibiotics?
Answer: AMI affects the mucosa first and bacterial trans-
location is an early event in the progression of AMI. Broad-
spectrum antibiotic cover should be given.
Background: Loss of the integrity of the mucosal bar-
rier facilitates bacterial translocation and occurs in the early 
stages of AMI. Although no specific studies have examined 
the role of prophylactic antibiotics in AMI, broad spectrum 
antibiotics (such as a penicillin or a third generation cepha-
losporin in combination with metronidazole) would be 
expected to reduce the consequences of bacterial transloca-
tion and should be given early [107].
Recommendation: Broad spectrum antibiotics should 
be administered early in the course of AMI (LOE: IV).
What is the specific treatment for AMI?
Arterial embolism (EAMI)
Answer: Open embolectomy is widely used in this sce-
nario. However, if expertise and appropriate resources are 
available, and there is no evidence of bowel necrosis, endo-
vascular techniques should be attempted.
Background: The established treatment is open surgi-
cal embolectomy. However, an increasing number of cases 
of successful percutaneous treatment have been reported 
with overall results comparable to the open approach [91, 
106].
Open embolectomy is usually performed via a mid-
line incision approaching the SMA just below the pan-
creas at the mesenteric root [98]. A transverse arteri-
otomy is then made after proximal and distal clamping 
and embolectomy catheters are used to clear the artery 
proximally and distally. High pressure proximal flushing 
should be avoided so as not to dislodge the thrombus in 
the aorta and produce further emboli. After completing 
the thrombectomy the artery should be flushed gently 
with heparinized saline. The arteriotomy is then closed in 
a standard fashion.
Endovascular embolectomy is achieved by percutaneous 
mechanical aspiration [108] or thrombolysis [109, 110] and 
permits percutaneous transluminal angioplasty (PTA), if 
necessary, with or without stenting [111, 112].
Recommendation: In cases where immediate surgi-
cal intervention is not required the decision to perform 
endovascular or open vascular surgery for EAMI should be 
determined by the personal experience and technical capa-
bilities of the surgeon and the available resources (LOE: 
IV).
When EAMI is identified during a laparotomy an open 
embolectomy should be performed (LOE: IV).
Arterial thrombosis (TAMI)
Answer: Endovascular treatment should be the first choice 
for TAMI whenever possible.
Background: Endovascular treatment should be con-
sidered as soon as possible for acute thrombosis of a dis-
eased superior mesenteric artery (SMA) [91, 98, 106, 113, 
114]. This should be performed before intestinal infarction 
occurs and when the ischaemia is potentially reversible. 
The commonest interventions are PTA and stenting. Other 
endovascular techniques include percutaneous aspiration 
thrombectomy, local fibrinolysis or intra-arterial drug per-
fusion (such as heparin or papaverine).
If surgery is needed to resect ischaemic bowel before 
vascular intervention, or when percutaneous treatment has 
failed, retrograde open mesenteric stenting (ROMS) has 
been suggested [113].
Conventional bypass surgery is another option [98]. 
There are a variety of bypass procedures, providing either 
antegrade or retrograde flow, with vein or synthetic grafts. 
An antegrade bypass from supraceliac aorta to superior 
mesenteric trunk using an endogenous vein graft will give 
the best result. An alternative approach would be a renal-
mesenteric bypass. However, the most practical option for 
proximal mesenteric atherosclerotic occlusive disease is 
a retrograde bypass from common iliac with a synthetic 
graft.
Where vascular expertise is not available it may be rea-
sonable to resect the necrotic bowel first and transfer the 
patient for urgent interventional angiography or vascular 
surgery [91].
Recommendations: When bowel integrity has not been 
compromised, endovascular techniques should be per-
formed as first line treatment for TAMI (LOE: III).
When a laparotomy has been performed for TAMI the 
choice of vascular intervention will depend on available 
resources and expertise (LOE: IV).
When vascular expertise is not available it may be rea-
sonable to resect the necrotic bowel first and transfer the 
patient for urgent interventional angiography or vascular 
surgery (LOE: III).
Venous ischaemia (VAMI)
Answer: The first line treatment for mesenteric venous 
thrombosis is anticoagulation.
Background: VAMI is usually managed without sur-
gery. Anticoagulation with a continuous infusion of unfrac-
tionated or low molecular weight heparin is the first line 
treatment for VAMI and should also be started in patients 
diagnosed at operation [80, 91, 98, 106, 115–117]. Iso-
lated thrombosis of the superior mesenteric vein is usually 
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compensated by sufficient collateral circulation. However, 
additional complete thrombosis of the portal vein leads to 
venous infarction of segments of small intestine of varying 
severity and may require laparotomy.
Patients who deteriorate during medical treatment can 
be considered for endovascular treatment. Many techniques 
have been described such as transjugular intrahepatic por-
tosystemic shunting (TIPS) with mechanical aspiration 
thrombectomy and direct thrombolysis, percutaneous tran-
shepatic thrombolysis, indirect thrombolysis via the SMA 
and thrombolysis via a surgically placed superior mesen-
teric vein (SMV) catheter.
A number of case-series advocate prompt direct throm-
bolysis on the basis of reported reduction in both early 
complications (infarction) and late sequelae (portal hyper-
tension) [116]. Contraindications to thrombolytic treatment 
are well established and can be divided into absolute (cen-
tral nervous system tumours, recent haemorrhagic stroke, 
gastrointestinal (GI) bleed and uncontrolled hypertension) 
and relative (pregnancy, remote history of GI bleeding, and 
recent major surgery).
Recommendations: Systemic anticoagulation should be 
started as soon as possible in VAMI (LOE: III).
Endovascular intervention should be offered to patients 
with VAMI who deteriorate during medical therapy (LOE: 
IV).
Non‑occlusive mesenteric ischaemia (NOMI)
Answer: The first line treatment for NOMI is medical ther-
apy with direct infusion of vasodilators into the SMA.
Background: The treatment of NOMI is based on cor-
recting the clinical or pharmacological conditions that gen-
erate splanchnic vasoconstriction, improving mesenteric 
perfusion and early recognition and resection of infarcted 
bowel [99].
The main factor in improving mesenteric perfusion is 
the restoration of circulatory volume and hemodynamic 
stability coupled with the use of vasodilators administered 
directly into the SMA in order to reverse the intestinal 
vasospasm that causes ischemia.
The diagnosis of NOMI should be confirmed by selec-
tive mesenteric angiography and, if there are no contraindi-
cations, the infusion of vasodilators directly into the SMA 
[90]. The best vasodilator drug appears to be prostaglandin 
E1 (alprostadil) given as a 20 mcg bolus followed by 60–80 
mcg/24 h infusion [90]; papaverine (30–60 mg/h) has been 
shown to reduce the mortality rate for NOMI from 70 to 
50–55 % and is an acceptable alternative [1, 10]. Other 
prostacyclin analogues have also been used [61].
The decision to intervene surgically is based on the pres-
ence of peritonitis, perforation, or overall worsening of the 
patient’s condition [99].
Recommendation: NOMI should be managed by cor-
recting the underlying cause wherever possible and improv-
ing mesenteric perfusion by direct infusion of vasodilators. 
Infarcted bowel should be excised (LOE: III).
How should a patient with peritonitis secondary to AMI 
be managed?
Answer: The common feature in the management of AMI 
is the need for surgical exploration in the presence of peri-
tonitis. Patients with AMI and signs of peritonitis should 
undergo immediate surgery if comorbidities and clinical 
condition make curative treatment possible. Surgical inter-
vention should also be considered if the patient’s condition 
deteriorates. With severe pre-existing medical conditions, 
pre-terminal state or extreme old age, the decision to pro-
ceed to laparotomy may not be appropriate.
Background: Across the literature there is agreement that 
peritonitis secondary to bowel necrosis mandates surgery 
without delay if curative treatment is to be achieved [98, 
106]. All other priorities (type of AMI, level of occlusion, 
etc.) are secondary and should be managed accordingly.
Recommendation: Patients with AMI and signs of peri-
tonitis should undergo immediate surgery if comorbidities 
and clinical condition make curative treatment possible 
(LOE: III).
Patients considered unsalvageable should have palliative 
care (LOE: IV).
What is the role of Damage Control Surgery in AMI?
Answer: Damage Control (DCS) is the surgical modality 
of choice in the critically ill patient with AMI.
Background: Patients with AMI who have severe sepsis 
or septic shock and undergo life-saving surgery should have 
a damage control approach. [118–121]. This includes imme-
diate laparotomy with resection of ischaemic bowel (and no 
anastomosis or stoma), open thrombectomy (if indicated), 
transfer to the intensive care unit to continue resuscitation 
prior to planned definitive procedures [122]. A temporary 
abdominal closure via a negative pressure wound therapy 
(NPWT) device should be considered since they have been 
shown to promote wound healing and facilitate subsequent 
abdominal closure [123, 124]. A scheduled ‘second look’ 
procedure should be performed within 48 h [125, 126].
Recommendation: Patients with AMI who have severe 
sepsis or septic shock should undergo life-saving damage 
control surgery (DCS) (LOE: III).
How should bowel viability be assessed at operation?
Answer: Assessment is based on the macroscopic appearance 
of the bowel: its colour, motility and bleeding of cut ends.
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Background: Necrotic bowel will be clearly identifi-
able at laparotomy [122, 127]. The viability of the remain-
ing bowel should be determined after the patient has been 
adequately resuscitated and any resection/revascularization 
performed [122]. In the acute setting, hypotension, vascu-
lar impairment and the concurrent use of vasopressors may 
confound this assessment and could result in excessive 
resection [106]. It is often better to adopt a damage limita-
tion approach and schedule a second-look procedure under 
these circumstances.
Intra-operative assessment with Doppler ultrasound of 
the vascular arcade, [128, 129], fluorescein angiography 
[127, 130] and indocyanine green angiography [131] have 
shown promise, but not been used extensively.
Recommendations: Necrotic bowel should be removed 
if the patient is considered salvageable (LOE: III).
Ischemic bowel should be reassessed after adequate fluid 
resuscitation and revascularization. If any doubt remains 
about the viability of the bowel, a second-look procedure 
should be performed (LOE: IV).
What limits should be observed in extensive bowel 
resection?
Answer: The removal of large amounts of small bowel can 
result in short bowel syndrome (SBS) and intestinal failure. 
SBS is associated with poor quality of life and a morbidity/
mortality which increases with age and comorbidities. Thus 
extensive resections should be carefully considered.
Background: Vascular occlusion in TAMI usually 
occurs in the proximal SMA and the consequent ischemia 
may extend from the terminal portion of the duodenum 
to the transverse colon [36]. In contrast, in EAMI most 
emboli lodge in the superior mesenteric artery distal to the 
origin of the middle colic artery. This maintains perfusion 
of the inferior pancreaticoduodenal arteries and spares the 
proximal jejunum from ischaemia [10, 36, 132]. However, 
up to 15 % of emboli in EAMI lodge at the origin of the 
SMA causing more extensive ischaemia.
Short bowel syndrome requiring total parenteral nutri-
tion (TPN) has been reported in 13–31 % of long-term sur-
vivors of AMI [9, 21, 31] and weight loss has been docu-
mented in 38 % [31]. SBS generally occurs when less than 
200 cm of functioning bowel remains [106].
Restoring bowel continuity will improve the functional 
results of extensive small bowel resection and may avoid 
long term TPN. It has been suggested that while permanent 
intestinal failure is likely with a residual 100 cm of small 
bowel and an end jejunostomy, the need for permanent 
TPN may be avoided with a minimum 65 cm of jejunum 
and a jejunocolic anastomosis, and 35 cm where the ile-
ocaecal region is preserved and a jejunoileal anastomosis 
performed [133].
When a residual small bowel length of 200 cm cannot be 
obtained, careful consideration should be given to the sig-
nificant risk of resection, particularly in the elderly patients 
and in those with significant co-morbidities. In younger 
patients the option of long term parenteral nutrition or the 
option of subsequent intestinal transplantation could make 
a more extensive resection reasonable.
Recommendation: The benefits of extensive small 
bowel resection should be balanced against the resultant 
quality of life, morbidity and mortality especially in elderly 
patients. Restoration of bowel continuity following exten-
sive resection will improve functional results and may 
avoid the need for long term TPN (LOE: III).
When is the most appropriate time to perform an 
anastomosis in a patient with AMI who needs bowel 
resection?
Answer: An anastomosis should be performed only in 
adequately resuscitated and stable patients when there is no 
question about the viability of the bowel.
Background: Bowel anastomosis should be avoided in 
the presence of severe sepsis or septic shock or when the 
patient is inadequately resuscitated. Where limited necrosis 
is found, there is no doubt about the viability of the remain-
ing bowel, the patient has been adequately resuscitated 
and there is no evidence of shock, some authors advocate 
anastomosis with a planned second-look [94]. Laparoscopy 
can be useful in this circumstance [126]. There are no pub-
lished studies that compare anastomotic techniques in AMI.
Stomas avoid the risks of anastomotic failure and per-
mit easy examination of the bowel by inspection and/
or endoscopy [106]. A mucous fistula of the distal bowel 
may be used for re-feeding in patients with very proximal 
jejunostomies [134]. Continuity can be restored later if 
appropriate.
Recommendation: Anastomosis should be avoided in 
patients with shock or multiple organ dysfunction (LOE: 
III).
If during a second look procedure there is still doubt 
about the viability of the bowel it should be exteriorised 
(LOE: IV).
What is the role of second‑look laparotomy?
Answer: The second-look laparotomy plays an important 
role in AMI patients treated with curative intent and is the 
natural consequence of DCS.
Background: The use of second look procedures 
is associated with a significant reduction in morbidity 
(p = 0.002) [9] and mortality in selected patients leading 
to resection of ischaemic bowel in 38–71 % of cases [14, 
17, 18, 24, 29, 126, 135]. It is currently the best method to 
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assess bowel viability after revascularization and resuscita-
tion and may be the best time to perform an anastomosis 
and to close the abdomen after DCS.
Recommendations: After DCS a planned second-look 
procedure should be performed within 48 h (LOE: III).
A scheduled second-look should also be considered 
when there is concern about the possible progression of 
bowel ischemia and there should be a low threshold for an 
“on demand” second look procedure in AMI particularly 
when a bowel anastomosis has been performed (LOE: III).
Can we improve outcomes in terms of mortality 
and morbidity?
Answer: Outcomes for AMI can be improved by rapid 
diagnosis, optimisation and intervention by revasculariza-
tion with or without resection.
Background: Mortality increases dramatically when 
symptoms have been present for more than 24 h in AMI. 
Numerous studies have shown that mortality is lowest 
if intervention is performed within 12 h of the onset of 
symptoms. [18, 22, 25, 58, 136–139]. This is supported 
by experimental work which has shown gut viability to 
be 100 % within the first 12 h of ischaemia. This drops to 
54 % between 12 and 24 h and 18 % beyond 24 h [140].
The development of symptoms in VAMI is usually 
slower than the other forms of AMI. A small retrospective 
study of VAMI over 23 years suggested that patients pre-
senting within 3 days of the onset of symptoms had poorer 
outcomes than those presenting with symptoms of longer 
duration. The first group were more likely to undergo lap-
arotomy within 12 h of hospital admission (83 vs. 20 %) 
[52]. This reflected rapid disease progression in the group 
that presented sooner. In studies comparing the four aetio-
logical types of AMI, VAMI has the lowest mortality (11–
30 %) [5, 22, 30].
Recommendation: To improve outcomes in AMI a 
prompt diagnosis should be achieved and revasculariza-
tion performed within 12 h from the onset of symptoms. 
Resection of non-viable bowel should be performed with-
out delay (LOE: III).
Is there a role for prevention?
Answer: The diagnosis of AMI is difficult and often 
delayed or overlooked. Primary prevention should be tar-
geted at managing the risk factors that predispose it. There 
is little direct evidence for the benefit of secondary prophy-
laxis of AMI.
Background: Since TAMI is usually a marker for 
advanced systemic atherosclerosis, it would seem rea-
sonable, where appropriate, to advise these patients to 
stop smoking, modify their diet, lose weight and exercise 
adequately. Diabetes and hypertension should be treated and 
the use of statins and antiplatelet therapy considered [141].
Up to 60 % of patients with TAMI have previous symp-
toms of chronic mesenteric ischaemia (CMI) [9]. The mor-
tality of elective surgical intervention for CMI in selected 
patients has been shown to be significantly lower than the 
same procedures performed for TAMI [32]. However, there 
is little evidence that elective intervention for CMI prevents 
TAMI.
One-third of patients with EAMI have inadequately 
treated atrial fibrillation at presentation [9] and a similar 
number will have further emboli [3]. These patients should 
be considered for anticoagulation [31].
Cho et al. advocate ‘vigilant surveillance and preserva-
tion of SMA patency’ after vascular reconstruction [32]. 
Although numbers were small, 60 % (3 of 5) of patients 
who were treated for graft stenosis with stent/angioplasty 
or further reconstruction had a successful outcome. How-
ever, all of these occlusions were symptomatic.
VAMI is usually secondary to a hypercoagulable state 
[3]. These patients should be investigated for thrombophilia 
and treated accordingly.
Recommendations: All patients with AMI should be 
advised to make appropriate lifestyle changes to reduce the 
consequences of vascular disease. Diabetes and hyperten-
sion should be treated (LOE: IV).
Patients with proven CMI should be considered for elec-
tive revascularization (LOE: IV).
Unless contraindicated, patients with emboli should be 
treated with life-long anticoagulation to reduce the risk of 
recurrence (LOE: IV).
Patients with mesenteric artery thrombosis are at high 
risk of coronary thrombosis and they should be offered 
anticoagulants or antiplatelet therapy and a statin to reduce 
this risk (LOE: IV).
Patients with mesenteric venous thrombosis should be 
investigated for thrombophilia and treated accordingly. 
Where indicated, they should have a minimum of 6 months 
of anticoagulation (LOE: III).
Patients who have vascular stents or bypass procedures 
should have graft surveillance or stent follow up with 
duplex scanning or CT angiography to enable early detec-
tion and management of stenosis and occlusion (LOE: IV).
Summary of recommendations
 1. Acute mesenteric ischaemia (AMI) should be 
suspected in patients with acute abdominal pain 
in whom there is no clear diagnosis, particularly 
when the pain is disproportionate to the physical 
examination findings and in the elderly with a his-
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tory of cardiovascular comorbidities (Level of evi-
dence: III).
 2. AMI secondary to an arterial embolism (EAMI) 
should be suspected in patients with atrial fibrilla-
tion who have a sudden onset of abdominal pain. 
AMI resulting from arterial thrombosis (TAMI) 
should be suspected in patients with evidence of 
atherosclerotic disease particularly with a recent 
history of postprandial syndrome. AMI due to 
venous thrombosis (VAMI) should be suspected in 
patients with hypercoagulable states. Non-occlu-
sive mesenteric ischaemia (NOMI) should be sus-
pected in critically ill patients with an unexpected 
deterioration in their clinical condition (Level of 
evidence: III).
 3. Unexplained abdominal pain after any invasive 
procedure, particularly involving vascular manipu-
lation, should lead to suspicion and investigation 
of AMI (Level of evidence: III).
 4. Management decisions should not be based exclu-
sively on clinical findings. However, patients with 
advanced age, late presentation, peritonitis and 
signs of organ failure are unlikely to benefit from 
invasive procedures and should be considered for 
palliative care only (Level of evidence: III).
 5. A normal serum lactate level does not exclude 
AMI and should not be used for diagnosis (Level 
of evidence: III).
 6. Routine laboratory tests reflect disease progression 
in AMI, but should not be used for diagnostic pur-
poses (Level of evidence: III).
 7. In cases of suspected AMI, multidetector comput-
erised tomography scanning (MDCT) with intra-
venous contrast should be performed immediately. 
The use of oral contrast will add significant delay 
to the MDCT and should be avoided (Level of evi-
dence: III).
 8. Percutaneous angiography should not be used for 
initial diagnosis of AMI except where NOMI is 
suspected (Level of evidence: III).
 9. There is insufficient evidence to support the rou-
tine use of laparoscopy in AMI (Level of evidence: 
IV).
 10. Supplementary oxygen should be given immedi-
ately to all patients with AMI (Level of evidence: 
III).
 11. Fluid volume status should be quickly assessed and 
fluid replacement should start promptly but should 
not delay diagnosis and intervention (Level of evi-
dence: IV).
 12. Crystalloids should be used for fluid replacement, 
hydroxyethyl starch should be avoided (Level of 
evidence: Ia).
 13. Vasopressor drugs should be avoided in AMI. If 
vasopressor drugs are required after adequate vol-
ume replacement, preference should be given to 
those with minimal effect on the splanchnic circu-
lation (Level of evidence: IV).
 14. Cardiac glycosides should not be used as first line 
treatment of atrial fibrillation/flutter in AMI (Level 
of evidence: IV).
 15. Broad spectrum antibiotics should be administered 
early in the course of AMI (Level of evidence: IV).
 16. In cases where immediate surgical intervention is 
not required the decision to perform endovascu-
lar or open vascular surgery for EAMI should be 
determined by the personal experience and tech-
nical capabilities of the surgeon and the available 
resources (Level of evidence: IV).
 17. When EAMI is identified during a laparotomy an 
open embolectomy should be performed (Level of 
evidence: IV).
 18. When bowel integrity has not been compromised, 
endovascular techniques should be performed as 
first line treatment for TAMI (Level of evidence: 
III).
 19. When a laparotomy has been performed for TAMI 
the choice of vascular intervention will depend on 
available resources and expertise (Level of evi-
dence: IV).
 20. When vascular expertise is not available it may be 
reasonable to resect the necrotic bowel first and 
transfer the patient for urgent interventional angi-
ography or vascular surgery (Level of evidence: 
III).
 21. Systemic anticoagulation should be started as soon 
as possible in VAMI (Level of evidence: III).
 22. Endovascular intervention should be offered to 
patients with VAMI who deteriorate during medi-
cal therapy (Level of evidence: IV).
 23. NOMI should be managed by correcting the 
underlying cause wherever possible and improving 
mesenteric perfusion by direct infusion of vasodi-
lators. Infarcted bowel should be excised (Level of 
evidence: III).
 24. Patients with AMI and signs of peritonitis should 
undergo immediate surgery if comorbidities and 
clinical condition make curative treatment possible 
(Level of evidence: III).
 25. Patients considered unsalvageable should have pal-
liative care (Level of evidence: IV).
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 26. Patients with AMI who have severe sepsis or septic 
shock should undergo life-saving damage control 
surgery (DCS) (Level of evidence: III).
 27. Necrotic bowel should be removed if the patient is 
considered salvageable (Level of evidence: III).
 28. Ischemic bowel should be reassessed after ade-
quate fluid resuscitation and revascularization. If 
any doubt remains about the viability of the bowel, 
a second-look procedure should be performed 
(Level of evidence: IV).
 29. The benefits of extensive small bowel resection 
should be balanced against the resultant quality of 
life, morbidity and mortality especially in elderly 
patients. Restoration of bowel continuity following 
extensive resection will improve functional results 
and may avoid the need for long term TPN (Level 
of evidence: III).
 30. Anastomosis should be avoided in patients with 
shock or multiple organ dysfunction (Level of evi-
dence: III).
 31. If during a second look procedure there is still 
doubt about the viability of the bowel it should be 
exteriorised (Level of evidence: IV).
 32. After DCS a planned second-look procedure 
should be performed within 48 h (Level of evi-
dence: III).
 33. A scheduled second-look should also be consid-
ered when there is concern about the possible pro-
gression of bowel ischemia and there should be 
a low threshold for an “on demand” second look 
procedure in AMI particularly when a bowel anas-
tomosis has been performed (Level of evidence: 
III).
 34. To improve outcomes in AMI a prompt diagno-
sis should be achieved and revascularization per-
formed within 12 h from the onset of symptoms. 
Resection of non-viable bowel should be per-
formed without delay (Level of evidence: III).
 35. All patients with AMI should be advised to make 
appropriate lifestyle changes to reduce the conse-
quences of vascular disease. Diabetes and hyper-
tension should be treated (Level of evidence: IV).
 36. Patients with proven CMI should be considered for 
elective revascularization (Level of evidence: IV).
 37. Unless contraindicated, patients with emboli 
should be treated with life-long anticoagulation to 
reduce the risk of recurrence (Level of evidence: 
IV).
 38. Patients with mesenteric artery thrombosis are at 
high risk of coronary thrombosis and they should 
be offered anticoagulants or antiplatelet therapy 
and a statin to reduce this risk (Level of evidence: 
IV).
 39. Patients with mesenteric venous thrombosis should 
be investigated for thrombophilia and treated 
accordingly. Where indicated, they should have a 
minimum of 6 months of anticoagulation (Level of 
evidence: III).
 40. Patients who have vascular stents or bypass proce-
dures should have graft surveillance or stent fol-
low up with duplex scanning or CT angiography to 
enable early detection and management of stenosis 
and occlusion (Level of evidence: IV).
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